Loading stock analysis…
Evidence Synthesis
Last synthesized: 22 Jul 2026, 15:32
Evidence Synthesis
TITANBIO's 53.35% gross margin accelerated to, up from 17.23%.
The company's .23% marginal operating leverage also accelerated. Revenue growth, however, slowed down with a .9% decline. The stock price rose marginally with a . Daily volume decreased with 25298 shares traded.
Source observations behind the synthesis narrative.
| Metric | Value | Trend | |
|---|---|---|---|
| GROSS_MARGIN | 53.35 % | 17.23 | ▲ |
| MARGINAL_OPERATING_LEVERAGE | 17.23 % | 14.49 | ▲ |
| REVENUE_GROWTH_YOY | 38.9 % | 66.3 | ▼ |
| PRICE_CHANGE_PERCENT | 0.07 % | — | - |
| DAILY_VOLUME | 25,298 shares | 34,801 | ▼ |
| CLOSE_PRICE | 429 INR | 428.7 | ▲ |